In a collaboration between neurosurgery and oncology, we introduce CSF-BAM, a minimally invasive assay that detects both solid tumors and hematologic malignancies in the CNS. The assay integrates immune profiling, aneuploidy, and mutation analysis from CSF, to provide a safe and highly specific alternative to brain biopsy with potential to transform patient care. https://aacrjournals.org/cancerdiscovery/article/15/10/2002/765950/Detection-of-Human-Brain-Cancers-using-Genomic-and